A Phase 1, Single-center, Randomized, Double-blind, Placebo-controlled, Single-dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Profiles of TG-1000 in Healthy Volunteers, and to Evaluate the Food Effect on Pharmacokinetics of Single Oral Dose of TG-1000 in Healthy Volunteers.
Latest Information Update: 08 Jan 2021
At a glance
- Drugs TG-1000 (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors TaiGen Biotechnology
- 16 Dec 2020 Status changed from recruiting to completed, according to a Taigen biotech media release.
- 31 Aug 2020 According to a TaiGen Biotechnology media release, based on the test results of the four dose groups, the dose for the phase 2 clinical trial will be determined.
- 31 Aug 2020 According to a TaiGen Biotechnology media release, the fifth and sixth dose groups and food cross-effect of this study will be carried out successively.